Latest Commercialization News

Lithium Universe Limited has secured a decade-long binding offtake agreement with Norah Mining Limited to supply spodumene concentrate for its Bécancour Lithium Refinery in Canada, reinforcing its North American lithium ambitions amid rising prices.

Prairie Lithium has begun installing grid power infrastructure at its Pad #1 site in Saskatchewan, marking a crucial step toward commercial lithium production with reliable, low-cost electricity.

Nimy Resources has dispatched its inaugural shipment of high-grade gallium ore from Western Australia to the United States, marking a significant step in establishing a secure Western supply chain for this critical mineral.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

5E Advanced Materials has successfully closed an oversubscribed US$36 million public offering, positioning itself to advance its boron operations and finalise key commercial contracts.

Adisyn Ltd has appointed Arye Kohavi, CEO of 2D Generation, as its new Managing Director to spearhead its semiconductor technology strategy following a strategic review and recent acquisition.

First Graphene has secured a strategic distribution and collaboration agreement with Syron GreenThrust Dynamics to supply its PureGRAPH products across India, SAARC nations, and the UAE, unlocking new industrial markets and potential local manufacturing.

Income Asset Management has resolved a protracted legal dispute with BGC involving former employees, agreeing to a $1.9 million settlement. A key shareholder has stepped in with a liquidity facility to support the company’s payment obligations.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

1414 Degrees has achieved a key milestone with its SiNTL silicon anode material reaching 500 mAh/g, matching current commercial standards ahead of schedule and setting sights on 600 mAh/g within a year.